

(CIN: L51219MH1980PLC329224)

Date: 10th May, 2022

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001

Script ID- MAYUKH; Scrip Code- 539519.

Subject: Update on Outcome of Board Meeting dated 10/02/2022 with respect to discrepancies received from BSE Dept. related to Segment Report filed by Company with Financial Result given by Auditors.

Reference: Board Meeting Outcome filed by Company to BSE dated 10/02/2022.

Dear Sir(s),

With respect to the subject matter we wish to inform that the company has submitted the Board Meeting Outcome dated 10/02/2022 for Approving Un-audited Financial Results for the quarter and nine months ended December, 2021 along with the Limited Review Report.

We wish to inform that the Segment Report submitted by the company with Financial Results for the quarter ended Dec, 2021 but in the same, segment name written as Company name instead of business segment name, in this regards we are further submitting herewith Segment Report issued by Auditors.

You are requested to take this on your record and acknowledge the receipt.

Thanking You,

Yours Faithfully

For, Mayukh Dealtrade Limited

Mit Tarunkumar Brahmbhatt

Managing Director

DIN 06520600

Encl: Segment Report.



MAYUKH DEALTRADE LIMITED CIN NO. L51219MH1980PLC329224

Office No. 101 on 1st Floor, Crystal Rose C.H.S. Datta Mandir Road, Mahavir Nagar, Kandivali West, Mumbai City MH 400067

Email ID.info@mayukh.co.in; www.mayukh.co.in; Contact no. 022-28684491,
Statement of Standalone unaudited Financial Result for the quarter and Year ended 31st December, 2021

			Rs In Lakhs				Rs In Lakhs				
	Particulars		- Quarter ended		Nine Mo	nth Ended		ended			
	Particulars	31st December 2021	30th September 2021	31st December 2020	31st December 2021	31st December 2020	31st March, 2021	31st March, 202			
	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Personal Control of the Control of t				
- 1	Revenue From Operations	20.20	58.14	39.78	132.67		audited	Audited			
,	Other Income	0.06	0.02	0.06	-0.02	84.06 0.26	0.32	42.			
	Total Income (I+II)	20.26	58.16	39.84	132.66	84.32	129,44	0,			
II	EXPENSES					17134	127,44	42.			
	Cost of materials consumed										
	Purchases of Stock-in-Trade Changes in inventories of finished goods.	24.15	43.71	24.76	89.81	61.97	76.70	41.			
	Stock-in - Frade and work-in-progress	8.18	-38,79	-19.39							
	Employee benefits expense	8.32	4.53	4.10	-40,17	-42.49	-56.37	-27.			
	Finance cost	0.20	0.01	0.01	18.32	295.00	23.72	4.			
	Depreciation and amortization expense	2.74	0.79	1.25		1.96	5,11	5.			
	Listing fee					1.30	1.71	0.			
	Commission Paid							7			
	Other expenses	9,34	13.33	6.24	25:30	14.03	18.98	16.0			
	Profit/(loss) before exceptional items and	52.92	23.58	16.97	93.26	53.00	69.84	42			
III	tax (I- IV)	-32.67	34.58	22.02							
IV	Exceptional Items		.14.38	22.87	39.40	31.32	59.60	0,			
· v	Profit/(loss) before tax (V-VI)										
VI	Tax expense:	-32.67	34.58	22.87	39,40	31.32	59.60	0.2			
- 11	(1) Current tax	-32.67						***			
	(2) Deferred tax	- 1	8.99	5.95	15.55	8.14	15.50				
	Profit (Loss) for the period from							-0.0			
VIII	continuing operations (VII-VIII)	-32.67	25.59	16.92	***						
	Profit/(loss) from discontinued operations		23.39	10.92	23.85	23.18	44.11	0.3			
	Tax expense of discontinued operations										
IX	Profit/(loss) from Discontinued operations (after tax) (X-XI)										
X	Profit/(loss) for the period (IX+XII)	-32.67	25.59	16.92	23.85	23.18	44.11	0,2			
XI	Other Comprehensive Income	-32.67	25.59	16.92	23.85	23.18	44.11	0.2			
	A (i) Items that will not be reclassified to										
	profit or loss										
	(ii) Income tax relating to items that will not be reclassified to profit or loss.					-					
	B (i) Items that will be reclassified to										
	profit or loss										
	(ii) become tax relating to items that will			*	-						
	be reclassified to profit or loss Total Comprehensive Income for the										
	period (XIII+XIV)(Comprising Profit										
	(Loss) and Other Comprehensive Income										
XII	for the period)	-32 67	25.59	16.92	23.85	23.18	44.11	0.2			
XIII	Earnings per equity share (for continuing operation):							0.2			
	1) Basic	(0.51)	0.40								
	(2) Diluted	(0.51)	0.40	0.53	0.37	0.72	1,38	0.0			
	Farnings per equity share (for discontinued		0.40	0.53	0.37	0.72	1,38	0.0			
	operation): (1) Basic										
	(2) Diluted	4 .									
	Earnings per equity share(for discontinued										
	& continuing operations)										
	1) Basic	-0.51	0.40	0.53	0.72						
	2) Diluted	-0.51	0.40	0.53	0.37	0.72	1.38	0.01			
ite:				4.73	0.37	0.72	1.38	0.01			
1	The above unaudited financial results were reviewed by Audit Committee	tee and approved by the D	oard of Directors in their	natina baldes that r	2022						
2	The futures for the corresponding president		a service of the their m	secong neid on 10th Febru	ary ,2022.						
	The figures for the corresponding previous period have been regrouped										
3	The Statutory auditors of the Company have carried out a "Limited Rev	riew" of the above results	as per Regulation 33 of the	SEBI (Listing Obligation	and Disclosure Requirement	ent) Regulations 2015					
6.0											
4	The Company has adopted Indian Accounting standards (Ind AS) with inder Section 133 of the Companies Act, 2013	effect from 01" April, 20	17 and accordingly, the ab	ove results have been own	sared in accordance with	ha Comment					
1	inder Section 133 of the Companies Act, 2013		27.00	are been prep	- Sum accordance with t	ne companies (Indian Ac	counting Standard) Ru	les, 2015 prescribed			
	The Ind AS compliant fine-solid assults and										
5	The Ind AS compliant financial result, pertaining to corresponding Q issue that such financial result provide a true and fair view of its affair	uarter and three month en	ded December, 31st. 2021	have not been subject to	limited review to Audit. I	lowever, the management	has exercised necessi	ary due deligence to			
	and the first that the state of										
6 7	he Company is engaged in the business of "Distributors" and "Medical	ire Business" therefore to	is only one mountable.	and to see the	1.50 100 5						
73		merenere, na	one reportable segn	sem in accordance with Inc	AS 108 "operating Segm	ents"					
1	mpact of COVID-19										
7	he company possible effects that may result from COVID-19 in the preparation of these interim condensed financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumption										
0	lating to the possible future uncertainties in the global economic conditions because of COVID-19, the Group has at the date of approval of these condensed financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumption ports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The innext of COVID-19, the other of the conditions that the carrying amount of these assets will be recovered. The innext of COVID-19, the other of the conditions that the carrying amount of these assets will be recovered. The innext of COVID-19 to other other of the conditions that the carrying amount of these assets will be recovered.										
0	ports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Group's financial statements, used internal and external sources of information including credit these interim condensed financial statements may differ from that estimated as at the date of approval										
1	he Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 10th. February, 2022. The Statutory Auditors of the Company have carried out a										
L	imited Review of the aforesaid results	approved the	and its releas	e at their respective meeting	ngs held on 10th February	, 2022. The Statutory Aug	litors of the Company I	have carried out a			
	lace: Mumbai										
1	ate:			11111							





Head Office: Office No. 215, 2nd Floor, Gundecha Ind. Estate, Akurli Road, Kandivali (E), Mumbai - 400 101.

Tel: +91 22-67337024 / +91 22-67337025 | E-mail: ssrvanbassocioates@gmail.com

LIMITED REVIEW REPORT

Independent Auditors Review Report on Standalone Quarterly Financial Results and Year to date results of the Company pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Review Report to
The Board of Directors.
MAYUKH DEALTRADE LIMITED
Office No. 101 on 1st Floor,
Crystal Rose C.H.S. Datta Mandir Road,
Mahavir Nagar, Kandivali West,
Mumbai City MH 400067,

- 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of MAYUKH DEALTRADE LIMITED ('the Company') for the quarter ended 31ST December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain

UDIN: 22403437ABEJWR8124



moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Standalone Unaudited financial results prepared in accordance with applicable accounting standards, notified pursuant to section 133 of the Companies Act 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

KARKA MEMBIND

For SSRV& Associates

Chartered Accountants FRN: 135901W

Vishnu Kant Kabra

Partner

M. No:- 403437 Place:- Mumbai Date:- 10-02-2022

UDIN : 22403437ABEJWR8124

MAYUKH DEALTRADE LIMITED

CIN NO. L51219MH1980PLC329224
Office No. 101 on 1st Floor, Crystal Rose C.H.S. Datta Mandir Road, Mahavir Nagar, Kandivali West, Mumbai City MH 400067

Email ID.info@mayukh.co.in; www.mayukh.co.in; Contact no. 022-28684491,
of consolidated unaudited Financial Result for the quarter and Year ended 31st December, 2021

			Rs In Lakhs Quarter ended		Nine Mor	ith Ended	Rs In Lakhs Year ended				
	Particulars			21-1 December 2020		31st December 2020	31st March, 2021	31st March, 2026			
		31st December 2021	30th September 2021	31st December 2020	31st December 2021						
	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	· Unaudited	audited	Audited			
R	evenue From Operations	21.22	58.14	39.78	132.67	84.06	129.12	42.5			
0	ther Income	0,06	0.02	0.06	-0.02	0.26	0.32	0.0			
	Total Income (I+II)	21.28	58.16	39,84	132.66	84.32	. 129,44	42.			
E	XPENSES										
C	ost of materials consumed				•		76.70	41.			
	urchases of Stock-in-Trade	29.29	43.71	24.76	89.81	61.97	76.70	41.			
	hanges in inventories of finished goods, tock-in -Trade and work-in-progress	8,18	-38,79	-19,39	-40.17	-42.49	-56.37	-27.			
-		8.90	4.53	4.10	18.32	295.00	23.72	4.			
	mployee benefits expense	0.20	0.01	0.01		0.05	5.11	5.			
-	Depreciation and amortization expense	2.74	0,79	1.25		1.96	1.71	0.			
-	isting fee										
_	ommission Paid										
-	Other expenses	9,40	13.33	6.24	25.30	14.03	18.98	16.			
	Total expenses (IV)	. 58.70	23.58	16.97	93.26	53.00	69,84	, 42.			
P	rofit/(loss) before exceptional items and										
1 0	ax (I- IV)	-37.43	34.58	22.87	39.40	31.32	59.60	0.			
	xceptional Items										
	Profit/(loss) before tax	.37.43	34.58	22.87	39.40	31.32	59.60	. 0.			
-	V-VI)	-37.43	34,36	66.07	.7.40	- Ande					
	ax expense:	-37.43	8.99	5.95	15.55	8.14	15.50				
-	1) Current tax		8.00	345	(5/2)	-	1,000	-0.			
	2) Deferred tax Profit (Loss) for the period from							-			
	continuing operations (VII-VIII)	-37.43	25.59	16.92	23.85	23.18	44,11	0			
-	Profit (loss) from discontinued operations										
_	Fax expense of discontinued operations		PROBLEM STATE								
	Profit/(loss) from Discontinued operations				The state of the state of						
X (after (ax) (X-XI)	-37.43	25.59		23.85	23.18	44.11	6			
(1	Profit/(loss) for the period (IX+XII)	-37.43	25.59	16.92	23.85	23.18	44.11	0			
	Other Comprehensive Income +							-			
	A (i) Items that will not be reclassified to										
	profit or loss (ii) Income tax relating to items that will										
	not be reclassified to profit or loss						-				
	B (i) Items that will be reclassified to										
	profit or loss				-		-	-			
	(ii) Income tax relating to items that will										
-	he reclassified to profit or loss Total Comprehensive Income for the		<u> </u>								
	period (XIII+XIV)(Comprising Profit										
	(Loss) and Other Comprehensive Income			14.02	23.85	23.18	44.11				
KII	for the period)	-37.43	25.5	16.92	23.02	2,7110	4.11				
CHI	Earnings per equity share (for continuing operation):										
-	(†) Basic	(0.58	0.4	0.53	0.37	0.72	1.38	(
	(2) Diluted	(0.58	0.4	0 0.53	0.37	0.7	1.38				
	Farmings per equity share (for discontinued					// 100					
	operation):				-			-			
	(1) Basic			·	<u> </u>	-	-	+			
	(2) Diluted						-	-			
	Earnings per equity share(for discontinued										
	& continuing operations)	-0.51	8 0.4	0 0.5	0.3	7 0.7.	2 1.33				
_	(1) Busic	-0.5				The second secon					
	(2) Diluted	-9.34	0.4	0.00							
le:											
1	The above unaudited financial results were reviewed by Audit Com-	mittee and approved by the	he Board of Directors in the	eir meeting held on 10th F	ebruary ,2022.						
2	The figures for the corresponding previous period have been regrou	ped / reclassified wherever	er necessary, to make them	comparable.							
-					1011 0						
3	The Statutory auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015										
	The second secon										
4	The Company has adopted Indian Accounting standards (Ind AS)	with effect from 01st Apr	il, 2017 and accordingly, t	he above results have been	prepared in accordance v	with the Companies (India)	n Accounting Standard) Rules, 2015 presen			
	under Section 133 of the Companies Act, 2013										
	The Ind AS compliant financial result, pertaining to corresponding Quarter and three month ended December, \$1st. 2021 have not been subject to limited review to Audit. However, the management has exercised necessary due deligence										
5	The Ind AS compliant financial result, pertaining to corresponding ensure that such financial result provide a true and fair view of its	ng Quarter and three mon	un ended December, 31st.	wist have not seen subje	er so miniou review to Att		Contract In				
2	services and over trimmonal result brosine a time official fall view of its										
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1										
6	The Company is engaged In the business of "Distributors" and "Medicare Business" therefore, has Two reportable segment in accordance with Ind AS 108 "operating Segments"										
1111	Impact of COVID-19										
	The company possible effects that may result from COVID-19 in the preparation of these interim condensed financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumption										
7	Leading the state of the state										
	resulting to the possive funder understanding contained recomments of the properties and related information and economic forecasts and expects that the earlying amount of these assets will be recovered. The impact of COVID-19 on the Group's financial statements may differ from that estimated as at the date of appropriate and related information and economic forecasts and expects that the earlying amount of these assets will be recovered. The impact of COVID-19 on the Group's financial statements may differ from that estimated as at the date of appropriate and related information and economic forecasts and expects that the earlying amount of these assets will be recovered. The impact of COVID-19 on the Group's financial statements may differ from that estimated as at the date of appropriate and the contract of the covidence of										
	of these interim condensed financial statements.										
	The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 10th. February, 2022. The Statutory Auditors of the Company have carried on										
	Limited Review of the aforesaid results.				_						





SSRV & Associates

Chartered Accountants

Head Office: Office No. 215, 2nd Floor, Gundecha Ind. Estate, Akurli Road, Kandivali (E), Mumbai - 400 101.

Tel: +91 22-67337024 / +91 22-67337025 | E-mail: ssrvanbassocioates@gmail.com

LIMITED REVIEW REPORT

Independent Auditors Review Report on Consolidated Quarterly Financial Results and Year to date results of the Company pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Review Report to
The Board of Directors.
MAYUKH DEALTRADE LIMITED
Office No. 101 on 1st Floor,
Crystal Rose C.H.S. Datta Mandir Road,
Mahavir Nagar, Kandivali West,
Mumbai City MH 400067,

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MAYUKH DEALTRADE LIMITED ('the Company') for the quarter ended 31ST December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain

UDIN: 22403437ABEJWR8124



moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above and based on the consideration of the review reports of the subsidiaries, nothing has come to our attention that causes us to believe that the accompanying Statement of Consolidated Unaudited financial results prepared in accordance with applicable accounting standards, notified pursuant to section 133 of the Companies Act 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

KABRA

For SSRV& Associates

Chartered Accountants

FRN: 135901W

Vishnu Kant Kabra

Partner

M. No:- 403437 Place:- Mumbai Date:- 10-02-2022

UDIN: 22403437ABEJWR8124

Segment reporting under Consolidated financial statements of the Company

Operating segments are reported in a manner consistent with internal reporting provided to the chief operating decision maker.

Director of the Company who is responsible for allocating resources and assessing performance of the operating segments, maker. has been identified as the cheif operating decision

Consolidated Segment wise information:

o. Particular		Quarter ended			Nine Months ended	
100000000000000000000000000000000000000	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
SEGMENT REVENUE	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
Distributors	20.26	58.16	39.84	132.66	84.32	129.44
Medicare Business	1.02	jest ([48]	-	81	1991
Segment Revenue	21.27	58.16	39.84	132.66	84.32	129.44
SEGMENT RESULT (PROFIT BEFORE TAX)						
Distributors	-32.67	34.58	22.87	39.40	31.32	59.60
Medicare Business	-4.76	194	1-0	8	#	190
Segment profit before tax	-37.43	34.58	22.87	39.40	31.32	59.60
SEGMENT ASSET						
Distributors	474.50	513.87	403.51	473.37	395.34	424.85
Medicare Business	_ [(4)	626	2	2)	120
Segment Revenue	474.50	513.87	403.51	473.37	395.34	424.85
SEGMENT LIABILITIES						
Distributors	474.50	513.87	403.51	473.37	395.34	424.85
Medicare Business	-	(40)	100	2	2)	323
Total liabilities	474.50	513.87	403.51	473.37	395.34	424.8
CAPITAL EMPLOYED						
Distributors	399.93	431.93	351.82	393.51	358.02	364.03
Medicare Business	-	1941	(+)	-	=	1991
DEPRECIATION & AMORTISATION						
Distributors	2.74	0.79	1.25	0.00	1.96	1.7
Medicare Business	75	-	171	-	T.	ASSESSED ASSESSED
Total depreciation and amortisation	2.74	0.79	1.25	0.00	1.96	1.71

